Jyong Biotech Ltd. Ordinary Shares
MENSHealthcare|Biotechnology|TW
$1.80
+0.15 (+9.09%)
Cash / Share
$0.02
About
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Stock Price
-95.2%(1Y)
1M
-14.3%
3M
-11.3%
6M
-12.2%
YTD
-54.4%
1Y
-95.4%
3Y
-82.2%
5Y
-82.2%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$136.8M
Employees27
CEOFu-Feng Kuo
IPO DateJun 17, 2025
Beta2.52
52-Week Range$1.43 – $41.2
Avg Volume48,492
ExchangeNASDAQ
Websitejyongbio.com
Ownership
Float36.9%
Shares Outstanding76.0M
Peers
Recent News
Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
Oct 21, 2026 · globenewswire.com
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
Oct 15, 2026 · globenewswire.com
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
Sep 3, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:21 AM